{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-154057","form_type":"8-K","ticker":"DYN","cik":"0001818794","company_name":"Dyne Therapeutics, Inc.","filed_at":"2025-07-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.111887+00:00","generated_at":"2026-05-18T10:24:34.011315+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Dyne Therapeutics prices $200M public offering of 24.2M shares at $8.25/share","bullets":["Gross proceeds of $200M; net proceeds ~$187M ($215.2M if underwriters exercise 30-day option for 3.6M additional shares).","Closing expected July 2, 2025; all shares sold by the company, resulting in dilution.","Cash runway extended into Q3 2027 inclusive of June 2025 $100M term loan from Hercules Capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-154057","json":"https://secwatch.observer/filing/0001193125-25-154057.json","markdown":"https://secwatch.observer/filing/0001193125-25-154057.md","text":"https://secwatch.observer/filing/0001193125-25-154057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818794/000119312525154057/0001193125-25-154057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818794/000119312525154057/d38498d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T10:24:34.011315+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}